{"product_id":"novartis","title":"Novartis: Drug Development and Licensing in Six Frameworks","description":"\u003cdiv class=\"pb-bundle\" data-pestel-bundle=\"v1\"\u003e\n\u003cdiv class=\"pb-intro\"\u003e\n\u003cp class=\"pb-eyebrow\"\u003eSix complementary perspectives. One company.\u003c\/p\u003e\n\u003ch2 class=\"pb-title\"\u003eNovartis Strategy Analysis Bundle\u003c\/h2\u003e\n\u003cp class=\"pb-lead\"\u003eNovartis is the workbook display name associated with NOVARTIS AG in the supplied regulatory record, where the issuer is classified as Pharmaceutical Preparations under SIC 2834. The supplied business context concerns a medicines business that develops treatments while working with biotech partners, specialist manufacturers and patient-support stakeholders.\u003c\/p\u003e\n\u003cp class=\"pb-lead\"\u003eThis context makes portfolio choices, partnership design and access to complex therapies particularly relevant analytical questions. The bundle helps examine how a pharmaceutical business can connect innovation, manufacturing capacity, regulated market access and patient use without treating possible conclusions as established company findings.\u003c\/p\u003e\n\u003cdiv class=\"pb-formats\"\u003e\n\u003cspan class=\"pb-format\"\u003e\u003cspan class=\"pb-file-icon pb-file-icon--excel\" aria-hidden=\"true\"\u003e\u003c\/span\u003eExcel files with structured analysis frameworks\u003c\/span\u003e\u003cspan class=\"pb-format\"\u003e\u003cspan class=\"pb-file-icon pb-file-icon--word\" aria-hidden=\"true\"\u003e\u003c\/span\u003eWord files with detailed company analysis\u003c\/span\u003e\n\u003c\/div\u003e\n\u003cp class=\"pb-note\"\u003e\u003cstrong\u003eAbout the images:\u003c\/strong\u003e Each image is a brief summary preview. Your purchase includes the Excel frameworks and Word files with the detailed company analysis. The previews are not the complete downloadable products.\u003c\/p\u003e\n\u003cnav class=\"pb-nav\" aria-label=\"Explore the six analyses\"\u003e\u003ca href=\"#bcg\"\u003eBCG Matrix\u003c\/a\u003e\u003ca href=\"#canvas\"\u003eCanvas\u003c\/a\u003e\u003ca href=\"#five-forces\"\u003eFive Forces\u003c\/a\u003e\u003ca href=\"#marketing-mix\"\u003eMarketing Mix\u003c\/a\u003e\u003ca href=\"#pestel\"\u003ePESTLE\u003c\/a\u003e\u003ca href=\"#swot\"\u003eSWOT Analysis\u003c\/a\u003e\u003c\/nav\u003e\n\u003c\/div\u003e\n\n\u003cdiv id=\"bcg\" class=\"pb-row\" tabindex=\"-1\" aria-labelledby=\"pb-heading-bcg\"\u003e\n\u003cdiv class=\"pb-copy\"\u003e\n\u003cdiv class=\"pb-heading\"\u003e\n\u003cspan class=\"pb-icon pb-icon--bcg\" aria-hidden=\"true\"\u003e\u003c\/span\u003e\u003ch3 id=\"pb-heading-bcg\" class=\"pb-heading-title\"\u003eBCG Matrix\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cp class=\"pb-question\"\u003eHow can Novartis compare therapy portfolios when development needs, market growth and competitive positions differ?\u003c\/p\u003e\n\u003cp\u003eA Novartis BCG Matrix provides a disciplined way to compare medicine categories or therapeutic priorities through market growth and relative market share. It frames the familiar Stars, Cash Cows, Question Marks and Dogs as analytical categories rather than assigning any Novartis product to a quadrant. That distinction matters in pharmaceuticals, where a promising scientific platform may require substantial clinical, regulatory and manufacturing investment before commercial scale is known. The framework helps organise discussions about where evidence, capital, launch preparation and lifecycle-management attention may be most consequential.\u003c\/p\u003e\n\u003cul class=\"pb-list\"\u003e\n\u003cli\u003e\n\u003cstrong\u003ePortfolio logic.\u003c\/strong\u003e Compare high-growth treatment opportunities with the relative strength needed to support investment and sustain established medicines.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eResource tension.\u003c\/strong\u003e Consider how specialised biologics or radioligand capabilities could change the resources required across different portfolio areas.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePractical use.\u003c\/strong\u003e Use the Excel matrix to structure candidate categories, then use the Word analysis to interpret the assumptions and strategic questions behind each comparison.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cdiv class=\"pb-outcome\"\u003e\n\u003cstrong\u003eWhat you can take away\u003c\/strong\u003e A clearer portfolio-priority discussion that separates measured market criteria from assumptions about future therapeutic opportunities.\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pb-visual\"\u003e\n\u003cspan data-pestel-preview=\"1\"\u003e\u003c\/span\u003e\u003cp class=\"pb-caption\"\u003eBCG Matrix summary preview. The full company analysis is provided in Excel and Word.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\n\u003cdiv id=\"canvas\" class=\"pb-row pb-row--reverse\" tabindex=\"-1\" aria-labelledby=\"pb-heading-canvas\"\u003e\n\u003cdiv class=\"pb-copy\"\u003e\n\u003cdiv class=\"pb-heading\"\u003e\n\u003cspan class=\"pb-icon pb-icon--canvas\" aria-hidden=\"true\"\u003e\u003c\/span\u003e\u003ch3 id=\"pb-heading-canvas\" class=\"pb-heading-title\"\u003eBusiness Model Canvas\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cp class=\"pb-question\"\u003eHow does Novartis connect scientific innovation, treatment delivery and economic value across its medicines business?\u003c\/p\u003e\n\u003cp\u003eThe Novartis Business Model Canvas examines the links among all nine building blocks: customer segments, value propositions, channels, customer relationships, revenue streams, key resources, key activities, key partnerships and cost structure. For this business context, the value proposition is not only a medicine itself but also the ability to develop, manufacture, distribute and support its appropriate use. Biotech alliances, licensing arrangements, targeted acquisitions and specialised CMOs are useful subjects for analysis because they can affect both the pipeline and the cost or capacity needed to deliver complex therapies. The Canvas helps test how these pieces reinforce one another rather than treating them as isolated functions.\u003c\/p\u003e\n\u003cul class=\"pb-list\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eStakeholder map.\u003c\/strong\u003e Examine the distinct needs of patients, clinical decision-makers, healthcare organisations and external innovation or manufacturing partners.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eValue chain links.\u003c\/strong\u003e Relate research, development, quality, supply and post-market support to channels, relationships and revenue logic.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePractical use.\u003c\/strong\u003e Populate the Excel blocks as a connected operating map and use the Word analysis to investigate the trade-offs between partnerships, internal capabilities and costs.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cdiv class=\"pb-outcome\"\u003e\n\u003cstrong\u003eWhat you can take away\u003c\/strong\u003e A joined-up view of how a pharmaceutical value proposition can depend on science, access, supply reliability and long-term stakeholder relationships.\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pb-visual\"\u003e\n\u003cspan data-pestel-preview=\"2\"\u003e\u003c\/span\u003e\u003cp class=\"pb-caption\"\u003eBusiness Model Canvas summary preview. The full company analysis is provided in Excel and Word.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\n\u003cdiv id=\"five-forces\" class=\"pb-row\" tabindex=\"-1\" aria-labelledby=\"pb-heading-five-forces\"\u003e\n\u003cdiv class=\"pb-copy\"\u003e\n\u003cdiv class=\"pb-heading\"\u003e\n\u003cspan class=\"pb-icon pb-icon--five-forces\" aria-hidden=\"true\"\u003e\u003c\/span\u003e\u003ch3 id=\"pb-heading-five-forces\" class=\"pb-heading-title\"\u003ePorter's Five Forces\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cp class=\"pb-question\"\u003eWhich industry pressures may shape Novartis's ability to earn returns from innovative medicines?\u003c\/p\u003e\n\u003cp\u003eNovartis Porter's Five Forces analysis looks beyond individual products to the structure of pharmaceutical competition. Rivalry can involve competing treatment approaches, patent timing, clinical evidence and commercial execution. Supplier power may be especially relevant where advanced inputs, specialist manufacturing expertise or radioligand capacity are limited. Buyer power can arise through healthcare systems, payers and purchasing organisations that evaluate clinical value and affordability. The threat of new entrants is moderated by scientific, regulatory and manufacturing barriers, while substitutes include alternative ways of treating or managing the same patient need, not only similar medicines. This lens helps distinguish a force to investigate from a claimed force score.\u003c\/p\u003e\n\u003cul class=\"pb-list\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eCompetitive boundaries.\u003c\/strong\u003e Define rivalry around therapeutic need, clinical differentiation and access conditions rather than a simplistic list of named competitors.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDependency exposure.\u003c\/strong\u003e Test where external suppliers, contract capacity or specialised technology could affect speed, quality or negotiating leverage.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePractical use.\u003c\/strong\u003e Use the Excel framework to record evidence and questions for each force, with the Word analysis supplying fuller context for the industry interpretation.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cdiv class=\"pb-outcome\"\u003e\n\u003cstrong\u003eWhat you can take away\u003c\/strong\u003e A structured picture of the external bargaining and substitution pressures that can influence pharmaceutical portfolio economics.\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pb-visual\"\u003e\n\u003cspan data-pestel-preview=\"3\"\u003e\u003c\/span\u003e\u003cp class=\"pb-caption\"\u003ePorter's Five Forces summary preview. The full company analysis is provided in Excel and Word.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\n\u003cdiv id=\"marketing-mix\" class=\"pb-row pb-row--reverse\" tabindex=\"-1\" aria-labelledby=\"pb-heading-marketing-mix\"\u003e\n\u003cdiv class=\"pb-copy\"\u003e\n\u003cdiv class=\"pb-heading\"\u003e\n\u003cspan class=\"pb-icon pb-icon--marketing-mix\" aria-hidden=\"true\"\u003e\u003c\/span\u003e\u003ch3 id=\"pb-heading-marketing-mix\" class=\"pb-heading-title\"\u003eMarketing Mix (4Ps)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cp class=\"pb-question\"\u003eHow should a regulated medicines business align its offering, access route and communications with stakeholder needs?\u003c\/p\u003e\n\u003cp\u003eA Novartis Marketing Mix considers Product, Price, Place and Promotion in a context where treatment decisions and patient access are shaped by evidence, regulation and healthcare delivery. Product analysis can examine clinical use, formulation, service support and the operational demands of complex therapies. Price is a question of value, reimbursement and affordability frameworks rather than an invented list price. Place covers the routes through which treatments reach care settings, including the supply coordination required for specialised products. Promotion should be assessed through compliant, evidence-based communication to relevant professional and stakeholder audiences. The four elements are most useful when considered together: an advanced therapy cannot deliver its intended value if access, supply and understanding do not match the product proposition.\u003c\/p\u003e\n\u003cul class=\"pb-list\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eProduct fit.\u003c\/strong\u003e Assess how treatment characteristics and patient-support needs may influence the broader offering beyond the medicine alone.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAccess design.\u003c\/strong\u003e Compare reimbursement, distribution and care-setting questions that can affect availability and appropriate use.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePractical use.\u003c\/strong\u003e Use the Excel 4Ps structure to organise market-access questions, then consult the Word analysis for the regulated-business rationale behind each area.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cdiv class=\"pb-outcome\"\u003e\n\u003cstrong\u003eWhat you can take away\u003c\/strong\u003e A practical way to connect therapeutic value with the pricing, channel and communication choices needed for responsible market access.\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pb-visual\"\u003e\n\u003cspan data-pestel-preview=\"4\"\u003e\u003c\/span\u003e\u003cp class=\"pb-caption\"\u003eMarketing Mix summary preview. The full company analysis is provided in Excel and Word.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\n\u003cdiv id=\"pestel\" class=\"pb-row\" tabindex=\"-1\" aria-labelledby=\"pb-heading-pestel\"\u003e\n\u003cdiv class=\"pb-copy\"\u003e\n\u003cdiv class=\"pb-heading\"\u003e\n\u003cspan class=\"pb-icon pb-icon--pestel\" aria-hidden=\"true\"\u003e\u003c\/span\u003e\u003ch3 id=\"pb-heading-pestel\" class=\"pb-heading-title\"\u003ePESTLE Analysis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cp class=\"pb-question\"\u003eWhich external changes should Novartis monitor when planning research, supply and patient access?\u003c\/p\u003e\n\u003cp\u003eNovartis PESTLE analysis, also commonly called PESTEL, separates external influences into Political, Economic, Social, Technological, Legal and Environmental dimensions. Political and legal questions can include medicine regulation, approval pathways, intellectual-property rules and public-health priorities. Economic analysis can explore healthcare funding, reimbursement pressure, exchange exposure and the cost of specialist capacity without assuming a particular rate or policy change. Social factors include demographics, patient expectations and adherence needs. Technological change is relevant to discovery platforms, data capabilities, biologics and radioligand production. Environmental considerations can examine resource use, resilient supply and manufacturing expectations. Keeping these dimensions separate helps avoid mistaking external uncertainty for an internal company weakness.\u003c\/p\u003e\n\u003cul class=\"pb-list\"\u003e\n\u003cli\u003e\n\u003cstrong\u003ePolicy horizon.\u003c\/strong\u003e Track questions around regulatory review, health-system priorities and market-access rules that may influence launch planning.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eTechnology signals.\u003c\/strong\u003e Consider how emerging science and production methods could create opportunities as well as capability requirements.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePractical use.\u003c\/strong\u003e Organise external signals in the Excel PESTLE framework and use the Word analysis to connect them to relevant strategic responses for a medicines business.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cdiv class=\"pb-outcome\"\u003e\n\u003cstrong\u003eWhat you can take away\u003c\/strong\u003e An external-environment checklist that supports more deliberate monitoring of changes beyond the company's direct control.\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pb-visual\"\u003e\n\u003cspan data-pestel-preview=\"5\"\u003e\u003c\/span\u003e\u003cp class=\"pb-caption\"\u003ePESTLE Analysis summary preview. The full company analysis is provided in Excel and Word.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\n\u003cdiv id=\"swot\" class=\"pb-row pb-row--reverse\" tabindex=\"-1\" aria-labelledby=\"pb-heading-swot\"\u003e\n\u003cdiv class=\"pb-copy\"\u003e\n\u003cdiv class=\"pb-heading\"\u003e\n\u003cspan class=\"pb-icon pb-icon--swot\" aria-hidden=\"true\"\u003e\u003c\/span\u003e\u003ch3 id=\"pb-heading-swot\" class=\"pb-heading-title\"\u003eSWOT Analysis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cp class=\"pb-question\"\u003eHow can Novartis distinguish its controllable capabilities from external opportunities and risks?\u003c\/p\u003e\n\u003cp\u003eA Novartis SWOT analysis brings the other lenses together while preserving an essential distinction: strengths and weaknesses are internal, whereas opportunities and threats arise externally. Potential internal themes to assess include scientific expertise, development processes, partnership-management capability, manufacturing know-how and the complexity of coordinating specialised therapies. These are prompts for evaluation, not confirmed ratings. External opportunities may relate to unmet medical need, new technology or expanding treatment possibilities; external threats may involve competition, regulatory uncertainty, supply constraints or changing payer expectations. The value of SWOT is in testing whether an internal capability genuinely supports an external opportunity, and whether a weakness increases exposure to a particular threat.\u003c\/p\u003e\n\u003cul class=\"pb-list\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eClassification discipline.\u003c\/strong\u003e Keep internal resources and constraints separate from market, policy and competitive conditions so priorities do not become blurred.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStrategic fit.\u003c\/strong\u003e Explore where partnership networks or specialist manufacturing access may support opportunity capture or reduce operational vulnerability.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePractical use.\u003c\/strong\u003e Use the Excel grid to compare linked themes and the Word analysis to develop evidence-based questions before turning them into priorities.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cdiv class=\"pb-outcome\"\u003e\n\u003cstrong\u003eWhat you can take away\u003c\/strong\u003e A balanced starting point for relating Novartis's possible capabilities and constraints to the opportunities and threats around its medicines business.\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pb-visual\"\u003e\n\u003cspan data-pestel-preview=\"6\"\u003e\u003c\/span\u003e\u003cp class=\"pb-caption\"\u003eSWOT Analysis summary preview. The full company analysis is provided in Excel and Word.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\n\u003cdiv class=\"pb-closing\"\u003e\n\u003ch3\u003eConnect portfolio choices with the operating context\u003c\/h3\u003e\n\u003cp\u003eTogether, the six perspectives help turn broad questions about Novartis into connected portfolio, business-model, industry, market-access and risk discussions. The Excel frameworks provide structured places to compare issues, while the detailed Word analysis supports interpretation and more considered strategic work.\u003c\/p\u003e\n\u003cp class=\"pb-source\"\u003e\u003cstrong\u003eCompany background:\u003c\/strong\u003e \u003ca href=\"https:\/\/www.sec.gov\/edgar\/search\/\" target=\"_blank\" rel=\"noopener noreferrer\"\u003eNovartis — SEC EDGAR issuer search\u003c\/a\u003e.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PESTEL Analysis","offers":[{"title":"Default Title","offer_id":55296250020188,"sku":"novartis-pestle-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0938\/8127\/0620\/files\/novartis.webp?v=1790950249","url":"https:\/\/pestel-analysis.com\/products\/novartis","provider":"PESTEL ANALYSIS","version":"1.0","type":"link"}